ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, includi...

Full description

Saved in:
Bibliographic Details
Published in:Virchows Archiv : an international journal of pathology 2021-04, Vol.478 (4), p.801-804
Main Authors: Uner, Meral, Alhasson, Bassam, Obhrai, Jagdeep, Bagnasco, Serena M
Format: Article
Language:English
Subjects:
Aged
Antibodies, Antineutrophil Cytoplasmic - metabolism
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Antineutrophil cytoplasmic antibodies
Autoimmune Diseases - chemically induced
Autoimmune Diseases - diagnosis
Autoimmune Diseases - immunology
Autoimmune Diseases - pathology
Biomarkers - metabolism
Brief Report
Cancer
Cancer immunotherapy
Enterocolitis
Glomerulonephritis
Glomerulonephritis - chemically induced
Glomerulonephritis - diagnosis
Glomerulonephritis - immunology
Glomerulonephritis - pathology
Humans
Immune checkpoint inhibitors
Immunotherapy
Kidney - drug effects
Kidney - metabolism
Kidney - pathology
Male
Medicine
Medicine & Public Health
Monoclonal antibodies
Necrosis
Nephritis
Pathology
PD-1 protein
Pembrolizumab
Side effects
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - drug therapy
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, including the kidney. Renal complications have rarely been reported compared with other irAEs and mostly consist of acute interstitial nephritis. Only rare cases of ICPI-related glomerulonephritis have been described. Herein, we report the case of an adult patient treated with pembrolizumab (anti-PD-1) for squamous cell carcinoma (SCC), who developed infectious enterocolitis, and ANCA-related with diffuse necrotizing crescentic glomerulonephritis, both conditions potentially linked to treatment with pembrolizumab.
ISSN:0945-6317
1432-2307
DOI:10.1007/s00428-020-02882-w